A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)

Key facts

Sponsor

University of Alabama at Birmingham

Principal Investigator

David W Kimberlin, MD, MD

University of Alabama at Birmingham

Intervention

Novel Antiviral Drug(drug)

Eligibility

All sexes

Timeline

2016 – 2017

Study locations (18)

• University of Alabama at Birmingham, Birmingham, Alabama, United States
• University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
• University of Colorado at Denver Health Sciences Center, Aurora, Colorado, United States
• Children's National Medical Center, Washington D.C., District of Columbia, United States
• University of South Florida School of Medicine, Tampa, Florida, United States
• Emory Children's Center, Atlanta, Georgia, United States
• Louisiana State University Health Science Center -Shreveport, Shreveport, Louisiana, United States
• Washington University in St Louis School of Medicine, St Louis, Missouri, United States
• Dartmouth Medical School, Lebanon, New Hampshire, United States
• Steven & Alexandra Cohen Children's Medical Center Of New York (CCMC), Manhasset, New York, United States
• University of Rochester Medical Center, Rochester, New York, United States
• Carolinas Medical Center - Charlotte, Charlotte, North Carolina, United States
• MetroHealth Medical Center, Cleveland, Ohio, United States
• Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
• Rhode Island Hospital, Providence, Rhode Island, United States
• +3 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.